$CCEL
CRYO CELL INTERNATIONAL INC

2021 Form 10-K Financial Statement

#000095017022001637 Filed on February 22, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $28.88M $7.541M $31.15M
YoY Change -7.26% -5.39% -2.1%
Cost Of Revenue $8.990M $2.313M $9.657M
YoY Change -6.91% -1.65% -3.77%
Gross Profit $19.90M $5.227M $21.49M
YoY Change -7.42% -6.95% -1.33%
Gross Profit Margin 68.88% 69.32% 68.99%
Selling, General & Admin $14.63M $3.490M $14.29M
YoY Change 2.32% -11.46% -4.01%
% of Gross Profit 73.51% 66.76% 66.52%
Research & Development $49.87K $7.060K $23.85K
YoY Change 109.09% -58.13% -20.88%
% of Gross Profit 0.25% 0.14% 0.11%
Depreciation & Amortization $1.039M $87.60K $372.3K
YoY Change 179.11% -9.55% -7.23%
% of Gross Profit 5.22% 1.68% 1.73%
Operating Expenses $14.68M $1.763M $14.32M
YoY Change 2.49% -55.99% -4.04%
Operating Profit $4.003M $3.464M $7.662M
YoY Change -47.75% 114.81% 51.33%
Interest Expense $1.379M -$349.6K $1.544M
YoY Change -10.69% -0.6% -9.36%
% of Operating Profit 34.45% -10.09% 20.15%
Other Income/Expense, Net -$1.392M $20.00 -$2.622M
YoY Change -46.92% -99.93% 56.9%
Pretax Income $2.611M $1.831M $5.039M
YoY Change -48.18% 41.77% 48.59%
Income Tax $527.7K $630.8K $1.415M
% Of Pretax Income 20.21% 34.46% 28.07%
Net Earnings $2.084M $1.200M $3.625M
YoY Change -42.52% 42.0% 58.23%
Net Earnings / Revenue 7.21% 15.91% 11.64%
Basic Earnings Per Share $0.26 $0.48
Diluted Earnings Per Share $0.25 $147.2K $0.45
COMMON SHARES
Basic Shares Outstanding 8.137M 7.546M 7.544M
Diluted Shares Outstanding 8.362M 8.140M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.339M $11.17M $10.45M
YoY Change -20.2% 50.01% 40.36%
Cash & Equivalents $8.263M $10.36M $10.36M
Short-Term Investments $75.41K $807.0K $88.48K
Other Short-Term Assets $1.270M $244.7K $856.3K
YoY Change 48.26% -6.03% 12.58%
Inventory $921.2K $927.3K $927.3K
Prepaid Expenses $611.6K
Receivables $5.253M $6.323M $6.323M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $15.78M $18.56M $18.56M
YoY Change -14.95% 20.59% 20.59%
LONG-TERM ASSETS
Property, Plant & Equipment $4.147M $1.641M $1.940M
YoY Change 113.76% -11.14% 5.06%
Goodwill $1.941M
YoY Change 0.0%
Intangibles $1.182M
YoY Change -5.42%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0% 0.0%
Other Assets $36.92M $26.00M $22.27M
YoY Change 65.78% 1.37% 0.54%
Total Long-Term Assets $44.88M $27.64M $27.64M
YoY Change 62.35% 0.53% 0.53%
TOTAL ASSETS
Total Short-Term Assets $15.78M $18.56M $18.56M
Total Long-Term Assets $44.88M $27.64M $27.64M
Total Assets $60.66M $46.20M $46.20M
YoY Change 31.3% 7.73% 7.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.490M $957.4K $957.4K
YoY Change 55.61% -30.07% -30.07%
Accrued Expenses $2.943M $2.898M $1.710M
YoY Change 72.17% 38.99% -18.01%
Deferred Revenue $9.183M
YoY Change 3.47%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.898M $3.100M $3.100M
YoY Change -38.77% 0.0% 0.0%
Total Short-Term Liabilities $21.07M $16.41M $16.41M
YoY Change 28.38% 6.39% 6.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.841M $2.841M
YoY Change -100.0% -51.48% -51.48%
Other Long-Term Liabilities $35.40M $32.45M $29.61M
YoY Change 19.57% -5.69% 3.7%
Total Long-Term Liabilities $35.40M $32.45M $32.45M
YoY Change 9.1% -5.69% -5.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.07M $16.41M $16.41M
Total Long-Term Liabilities $35.40M $32.45M $32.45M
Total Liabilities $56.48M $48.87M $48.87M
YoY Change 15.58% -1.95% -1.95%
SHAREHOLDERS EQUITY
Retained Earnings -$18.82M
YoY Change -16.15%
Common Stock $36.72M
YoY Change 1.84%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M
YoY Change 0.0%
Treasury Stock Shares $6.094M
Shareholders Equity $4.184M -$2.665M -$2.665M
YoY Change
Total Liabilities & Shareholders Equity $60.66M $46.20M $46.20M
YoY Change 31.3% 7.73% 7.73%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income $2.084M $1.200M $3.625M
YoY Change -42.52% 42.0% 58.23%
Depreciation, Depletion And Amortization $1.039M $87.60K $372.3K
YoY Change 179.11% -9.55% -7.23%
Cash From Operating Activities $7.926M $2.977M $8.467M
YoY Change -6.38% 148.3% 34.5%
INVESTING ACTIVITIES
Capital Expenditures $1.834M -$47.56K $99.96K
YoY Change 1734.69% -69.31% -84.91%
Acquisitions
YoY Change
Other Investing Activities -$5.106M $99.36K $457.5K
YoY Change -1216.24% -438.42% -1713.01%
Cash From Investing Activities -$6.951M $51.80K $357.5K
YoY Change -2044.47% -128.1% -153.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $249.4K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.073M -775.0K -5.004M
YoY Change -38.59% -57.24% -2.49%
NET CHANGE
Cash From Operating Activities 7.926M 2.977M 8.467M
Cash From Investing Activities -6.951M 51.80K 357.5K
Cash From Financing Activities -3.073M -775.0K -5.004M
Net Change In Cash -2.098M 2.254M 3.820M
YoY Change -154.92% -382.49% 662.49%
FREE CASH FLOW
Cash From Operating Activities $7.926M $2.977M $8.467M
Capital Expenditures $1.834M -$47.56K $99.96K
Free Cash Flow $6.092M $3.024M $8.367M
YoY Change -27.19% 123.4% 48.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-147528
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
527710
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20262
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1414727
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-11-30
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40767
CY2021 dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1800
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
CY2021 dei City Area Code
CityAreaCode
813
CY2021 dei Local Phone Number
LocalPhoneNumber
749-2100
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2021 dei Trading Symbol
TradingSymbol
CCEL
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
47607195
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8502618
CY2021 dei Auditor Firm
AuditorFirmId
344
CY2021 dei Auditor Name
AuditorName
Wipfli LLP
CY2021 dei Auditor Location
AuditorLocation
Atlanta, Georgia
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8263088
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10361125
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
75412
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
88476
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3078439
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2781668
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
558413
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
611627
CY2021Q4 us-gaap Inventory Net
InventoryNet
921213
CY2020Q4 us-gaap Inventory Net
InventoryNet
927318
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
711208
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
244696
CY2021Q4 us-gaap Assets Current
AssetsCurrent
15782507
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18556202
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3230204
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1640774
CY2021Q4 ccel Duke License Agreement
DukeLicenseAgreement
14651802
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1559693
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1181588
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9695363
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11064034
CY2021Q4 us-gaap Goodwill
Goodwill
1941411
CY2020Q4 us-gaap Goodwill
Goodwill
1941411
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
12010133
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10363967
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
916493
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
299089
CY2021Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
566470
CY2020Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
495029
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41649365
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26003118
CY2021Q4 us-gaap Assets
Assets
60662076
CY2020Q4 us-gaap Assets
Assets
46200094
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1489774
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
957390
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3057386
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2898211
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1898065
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
312067
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275570
CY2021Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
4957591
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9358696
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9183450
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21073579
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16414621
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31274214
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27200910
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
727371
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1509852
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2841214
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610989
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23632
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35404183
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32450608
CY2021Q4 us-gaap Liabilities
Liabilities
56477762
CY2020Q4 us-gaap Liabilities
Liabilities
48865229
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14665772
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8557326
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13633638
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7545613
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
146658
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
136336
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41586583
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36581600
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20812734
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16736193
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18819714
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2665135
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60662076
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46200094
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
28884902
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31147593
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8989736
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9657442
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14625311
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14294233
CY2021 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
CY2020 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-782481
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1940205
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49870
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23851
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
834845
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
166437
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
24881780
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
23485996
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
4003122
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
7661597
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-13064
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8130
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
773
CY2021 us-gaap Interest Expense
InterestExpense
1378926
CY2020 us-gaap Interest Expense
InterestExpense
1544017
CY2020 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1391891
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2622274
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2611231
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5039323
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
527710
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1414727
CY2021 us-gaap Net Income Loss
NetIncomeLoss
2083521
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-263573
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4248550
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3875849
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7926094
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8466603
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1833997
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3624596
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.48
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8137342
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7544494
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8361720
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8140180
CY2021 us-gaap Profit Loss
ProfitLoss
2083521
CY2020 us-gaap Profit Loss
ProfitLoss
3624596
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1039105
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
372289
CY2021 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
CY2020 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15111
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1032
CY2021 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-782481
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1940205
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-13064
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8130
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
301616
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
622120
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
536999
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
602965
CY2020 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1070900
CY2021 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1646166
CY2020 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1283973
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
56851
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
85062
CY2021 ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
287287
CY2020 ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
263686
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-532788
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
828594
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-53214
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
111367
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-210277
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-454943
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
466512
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-15701
CY2021 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-15549
CY2020 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
67606
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
532384
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-411721
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-11275
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1092131
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-280837
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99962
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
350000
CY2021 ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5106224
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10950
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
807447
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6951171
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
357485
CY2020 ccel Payments For Extinguishment Of Revenue Sharing Agreements
PaymentsForExtinguishmentOfRevenueSharingAgreements
1900000
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
249377
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4100000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3100000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1276417
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
CY2020 ccel Payment Of Earnout
PaymentOfEarnout
45000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3072960
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5004000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2098037
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3820088
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10361125
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8263088
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10361125
CY2020 ccel Operating Lease Liability And Right Of Use Asset Due To Adoption Of Asc842
OperatingLeaseLiabilityAndRightOfUseAssetDueToAdoptionOfAsc842
562775
CY2021 ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
904691
CY2021 ccel Patent Option Agreement Credit To Purchase Of Patents And Licenses
PatentOptionAgreementCreditToPurchaseOfPatentsAndLicenses
500000
CY2021 ccel Liabilities Incurred For The Purchase Of Patents And Licenses
LiabilitiesIncurredForThePurchaseOfPatentsAndLicenses
11374200
CY2021 ccel Taxes Payable Upon Net Exercise Of Stock Options
TaxesPayableUponNetExerciseOfStockOptions
147900
CY2021 us-gaap Stock Issued1
StockIssued1
3585172
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6952851
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
622120
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3624596
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2665135
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1128517
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3585172
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
301616
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
249377
CY2021 us-gaap Net Income Loss
NetIncomeLoss
2083521
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Risks</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company depends on one supplier for the source of its collection kits</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units. However, the Company believes that alternative sources of supply and manufacturing are available.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company depends on one third party, the National Marrow Donor Program, to manage the public umbilical cord stem cells that are needed for transplant.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During fiscal 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were no concentration of risks.</span></p>
CY2021 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
The Company depends on one supplier for the source of its collection kits
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
40632910
CY2021Q4 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9358696
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2021 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
49378
CY2020 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
49609
CY2021 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
95168
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
32508511
CY2020 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
21237546
CY2020 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
89471
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9358696
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9183450
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31274214
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
27200910
CY2021 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2020 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
CY2021 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
95168
CY2021 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
25787
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2021 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
36814240
CY2021 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
37884027
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36384360
CY2021 ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
17685646
CY2021 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
13437096
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40632910
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
398535
CY2020 ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
89471
CY2020 ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
21865
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
466141
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
CY2020 ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
38379247
CY2020 ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
38153618
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322960
CY2020 ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
17361697
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36384360
CY2021 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
CY2020 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2021 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2021 us-gaap Advertising Expense
AdvertisingExpense
841514
CY2020 us-gaap Advertising Expense
AdvertisingExpense
845454
CY2021 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-13000
CY2020 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-8000
CY2021 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Product Warranty and Cryo-Cell Cares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Program</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company increased the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payment warranty to a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program, nor has it incurred costs related to these warranties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at November 30, 2021 and November 30, 2020. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
2083521
CY2020 us-gaap Net Income Loss
NetIncomeLoss
3624596
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8137342
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7544494
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
224378
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
595686
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8361720
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8140180
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.48
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.25
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
302000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
622000
CY2021Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1164499
CY2020Q4 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
1284238
CY2021Q4 ccel Inventory Collection Kits
InventoryCollectionKits
42998
CY2020Q4 ccel Inventory Collection Kits
InventoryCollectionKits
33006
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2021Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10616576
CY2020Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
11991352
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1559693
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1181588
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
96381
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
96381
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
96381
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
86694
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
73132
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1110724
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1559693
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
89000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68000
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2021 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
56851
CY2020 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
85062
CY2021Q4 us-gaap Notes Payable
NotesPayable
1908433
CY2020Q4 us-gaap Notes Payable
NotesPayable
6008433
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
10368
CY2020Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
67219
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
1898065
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5941214
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1898065
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
2841214
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
1898065
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
5941214
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
118117
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
310364
CY2021 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
56851
CY2020 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
85062
CY2021 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
174968
CY2020 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
395426
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
28884902
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31147593
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8989736
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9657442
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
4003122
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
7661597
CY2021 us-gaap Interest Expense
InterestExpense
1378926
CY2020 us-gaap Interest Expense
InterestExpense
1544017
CY2021 us-gaap Interest Expense
InterestExpense
1378926
CY2020 us-gaap Interest Expense
InterestExpense
1544017
CY2021Q4 us-gaap Assets
Assets
60662076
CY2020Q4 us-gaap Assets
Assets
46200094
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2584091
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
602965
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
751848
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
346460
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2781668
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
536999
CY2021 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
564957
CY2021 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
324729
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3078439
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10752364
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9029333
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7522160
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7388559
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3230204
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1640774
CY2021 us-gaap Depreciation
Depreciation
229000
CY2020 us-gaap Depreciation
Depreciation
305000
CY2021 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
204000
CY2020 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
206000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
68959
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
47729
CY2021Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1673693
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
606828
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
888732
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
779444
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
426002
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
504306
CY2020Q4 ccel Accrued Income Taxes Benefit Current
AccruedIncomeTaxesBenefitCurrent
959904
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3057386
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2898211
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1468000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1757000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
740000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
598000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-34000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
68000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2174000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2423000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1024000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-847000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-622000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-161000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1646000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1008000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8507000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
7024000
CY2021Q4 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
68000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14751000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12860000
CY2020Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
134000
CY2021Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
-1050000
CY2020Q4 ccel Deferred Tax Assets Liabilities Tax Credit Carryforwards And Net Operating Losses
DeferredTaxAssetsLiabilitiesTaxCreditCarryforwardsAndNetOperatingLosses
-782000
CY2021Q4 ccel Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
172000
CY2020Q4 ccel Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
81000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1222000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
997000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1519000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1499000
CY2021Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1246000
CY2020Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1209000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
109000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
100000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
2341000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1895000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
414000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
567000
CY2021Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
499000
CY2020Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
483000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
19000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
19000
CY2021Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1374000
CY2020Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1482000
CY2021Q4 ccel Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
174000
CY2020Q4 ccel Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
81000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
12010000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10364000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
548358
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1061885
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
175654
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0673
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
282514
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0559
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
20262
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0077
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-147528
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0292
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
212217
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0813
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
6870
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0014
CY2021 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
34356
CY2021 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0131
CY2020 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
55372
CY2020 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.0110
CY2021 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
-334874
CY2021 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
-0.1282
CY2020 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
80692
CY2020 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.0160
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-93976
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0360
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
74922
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0147
CY2020 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
68102
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0135
CY2021 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
-34287
CY2021 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
-0.0131
CY2020 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
68102
CY2020 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.0135
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
527710
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2021
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1414727
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2798
CY2021 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50
CY2021 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
3533000
CY2020 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
1877000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.07
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.66
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
537443
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y2M19D
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.76
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
474409
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
5.25
CY2020 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
974276
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
24591
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49799
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
923056
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.99
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
93380
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.65
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
35900
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.07
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
66246
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.10
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
63034
CY2004Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2004Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17.600
CY2018Q3 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600
CY2021Q1 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
328877
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
318587
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15
CY2021 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
206000
CY2020 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
179000
CY2021 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
909829
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2021 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6113956
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
916493
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
299089
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
312067
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
275570
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
610989
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23632
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
923056
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
299202
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
339182
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
313996
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
295086
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y29D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y29D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
328752
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
278790
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
350000
CY2020Q2 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000
CY2020Q4 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
150000

Files In Submission

Name View Source Status
0000950170-22-001637-index-headers.html Edgar Link pending
0000950170-22-001637-index.html Edgar Link pending
0000950170-22-001637.txt Edgar Link pending
0000950170-22-001637-xbrl.zip Edgar Link pending
ccel-20211130.htm Edgar Link pending
ccel-20211130.xsd Edgar Link pending
ccel-20211130_cal.xml Edgar Link unprocessable
ccel-20211130_def.xml Edgar Link unprocessable
ccel-20211130_htm.xml Edgar Link completed
ccel-20211130_lab.xml Edgar Link unprocessable
ccel-20211130_pre.xml Edgar Link unprocessable
ccel-ex10_59.htm Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img14544128_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending